Published in Eur J Drug Metab Pharmacokinet on January 01, 1991
Screening paediatric rectal forms of azithromycin as an alternative to oral or injectable treatment. Int J Pharm (2012) 0.89
Pharmaceutical development and optimization of azithromycin suppository for paediatric use. Int J Pharm (2012) 0.79
Electric field effect in atomically thin carbon films. Science (2004) 45.10
Two-dimensional gas of massless Dirac fermions in graphene. Nature (2005) 22.35
Nanofabricated media with negative permeability at visible frequencies. Nature (2005) 2.08
A dynamic model for in-vitro evaluation of antimicrobial action by simulation of the pharmacokinetic profiles of antibiotics. J Antimicrob Chemother (1989) 0.99
[Kinetics of the antimicrobial effect in a dynamic system: the microcalorimetric recording method and choice of parameters for characterizing kinetic curves]. Antibiot Med Biotekhnol (1985) 0.85
Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio. Antimicrob Agents Chemother (2000) 0.82
[Principles for analyzing the kinetic curves of the antimicrobial effect in dynamic systems simulating the pharmacokinetic profiles of antibiotics]. Antibiot Med Biotekhnol (1987) 0.81
[Correlation between pharmacokinetic parameters of rifampicin and its biologically active metabolite as related to estimation of the relative bioavailability of the antibiotic]. Antibiot Khimioter (1996) 0.79
The antistaphylococcal pharmacodynamics of linezolid alone and in combination with doxycycline in an in vitro dynamic model. J Chemother (2011) 0.77
The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient doses. J Antimicrob Chemother (2001) 0.76
[Pharmacology of rifampicin]. Antibiotiki (1977) 0.76
[Microcalorimetric study of the kinetics of the antibacterial effect of third generation cephalosporins in an in vitro dynamic system]. Antibiot Khimioter (1991) 0.75
[PK/PD Modeling as a Tool for Predicting Bacterial Resistance to Antibiotics: Alternative Analyses of Experimental Data]. Antibiot Khimioter (2015) 0.75
[Individual schedule of administration of aminoglycosides with reference to anatomo-physiological and pathological factors]. Antibiot Khimioter (1989) 0.75
[Pharmacokinetics of amikacin in the perilymph and blood serum. An approach to the comparative evaluation of the potential ototoxicity of aminoglycoside antibiotics]. Antibiot Med Biotekhnol (1986) 0.75
[Comparative study of the relationship between the blood concentration of gentamicin and streptomycin and their muscle-relaxing activity]. Antibiotiki (1975) 0.75
[Pharmacokinetic validation of the nephrotoxic action of sisomycin. The relationship between nephrotoxicity and sisomycin concentration in the blood serum of rats]. Antibiotiki (1980) 0.75
[Optimal regime of intravenous administration of lincomycin in osteomyelitis]. Antibiotiki (1977) 0.75
[Interrelations in the changes in the pharmacokinetics and nephrotoxic effect of sisomycin as affected by cefazolin]. Antibiot Med Biotekhnol (1986) 0.75
[Drug forms of the fucidin antibiotic group]. Antibiotiki (1980) 0.75
[Elaboration of the procedures for the pharmacokinetic interpretation of aminoglycoside nephrotoxicity: the experimental evaluation of the safety of repeated gentamycin administration]. Antibiotiki (1982) 0.75
[Pharmacokinetics of the new antitumor antibiotic reumycin in an experiment: the prediction of the human pharmacokinetic profiles]. Antibiot Med Biotekhnol (1985) 0.75
[Pharmacokinetics of n-(5-oxynicotinoyl)-L-glutamic acid calcium salt upon bolus administration in rats and rabbits: interspecies extrapolation]. Eksp Klin Farmakol (2010) 0.75
[Pharmacokinetic monitoring of aminoglycoside therapy: an optimal method of administration of individualized doses of gentamicin and sisomicin]. Antibiot Khimioter (1991) 0.75
[Antibiotics as a component of prolonged-action preparations and materials for surgical use]. Antibiot Med Biotekhnol (1987) 0.75
[Data averaging in pharmacokinetic analysis: the population pharmacokinetics of cephalothin and cefazolin]. Antibiot Med Biotekhnol (1987) 0.75
[Dependence of the nephrotoxic effect of kanamycin on its concentration in the blood (an experimental study)]. Antibiotiki (1979) 0.75
[Pharmacokinetic basis of the nephrotoxic action of sisomycin. The pharmacokinetics of sisomycin in single and multiple administrations to rats]. Antibiotiki (1980) 0.75
[A dynamic system for the in vitro study of the kinetics of the antimicrobial effect of antibiotics in pharmacokinetic changes in their concentration]. Antibiot Med Biotekhnol (1985) 0.75
[Cephalosporins of the 1980s. New aminothiazolyloxyimino-cephalosporins and their sulfoxides]. Antibiot Khimioter (1990) 0.75
[Use of a 2-part model of i pharmacokinetics of gentaniycin for maintaining a constant blood concentration in infusion intravenous (an experimental study)]. Antibiotiki (1975) 0.75
[Clinical pharmacokinetics and the optimal intravenous ampicillin administration regimen in children]. Antibiotiki (1981) 0.75
[A pharmacokinetic basis for schedules for administering amikacin to newborn infants]. Pediatriia (1991) 0.75
[Cephalosporins of the 1980s. Aminothiazolylcephalosporins, non-glycine and phenylglycine cephalosporins, aminocephalosporins, cefamines, carbacephems and oxacephems]. Antibiot Khimioter (1990) 0.75
[Determination of bifonazole using HPLC in pharmacokinetic studies]. Antibiot Khimioter (1996) 0.75
[Comparative characteristics of the methods for assessing aminoglycoside extraction with the artificial kidney tobramycin clearance and dialyzability]. Antibiotiki (1981) 0.75
[Simulation of the pharmacokinetics of aminoglycosides in the kidneys: single and continuous intake of sisomicin and gentamicin by rats]. Antibiotiki (1983) 0.75
[Relationship between nephrotixic effect of gentamicin and streptomycin and their blood levels in laboratory animals]. Antibiotiki (1976) 0.75
Relationship between the blood concentration of the drug and its cumulative effect: a pharmacokinetic analysis of the nephrotoxic action of gentamicin and streptomycin. Pharmazie (1978) 0.75
[Experimental and clinical data on the ototoxic properties of aminoglycoside antibiotics (aminocyclitols)]. Antibiotiki (1983) 0.75
[Sisomycin pharmacokinetics in the perilymph and blood serum--an approach to predicting its ototoxic effect]. Antibiot Med Biotekhnol (1985) 0.75
[An analysis of the relationship between the serum concentration of streptomycin in experimental animals and its effect on the transmission of excitation at the neuromuscular synapses of skeletal musculature]. Antibiotiki (1974) 0.75
[Pharmacokinetics of protegentin, a combined preparation]. Antibiot Khimioter (1991) 0.75
[Non-traditional beta lactams--carbapenems, penems and monocyclic antibiotics]. Antibiot Khimioter (1991) 0.75
[Peridural anesthesia]. Sov Med (1972) 0.75
[Erythromycin pharmacokinetics in children after rectal and oral administration]. Antibiot Khimioter (1991) 0.75
[Cephalexin pharmacokinetics]. Antibiotiki (1981) 0.75
[Pharmacokinetic basis for using tobramycin and sisomicin in treating pyelonephritis of the transplanted kidney]. Antibiotiki (1983) 0.75
[Prediction of the pharmacokinetic profiles of doxycycline in humans based on the results of experiments in animals]. Antibiot Khimioter (1988) 0.75
[Importance of pharmacokinetic studies for antibiotic therapy in children with pneumonia]. Antibiot Khimioter (2000) 0.75
[Gentamycin and its drug forms]. Antibiotiki (1983) 0.75
[Modelling of rifampicin pharmacokinetics in experimental animals administered the drug intravenously and internally]. Antibiot Med Biotekhnol (1986) 0.75
[Utilization of mathematical modeling of the pharmacokinetics for working out the optimal regimens of antibiotic administration in pediatric practice]. Vopr Okhr Materin Det (1975) 0.75
[Fucidin in the surgical treatment of acute suppurative destruction of the lungs in children]. Pediatriia (1986) 0.75
[Correlation of dose-antimicrobial effect in modeling in vitro pharmacokinetic profiles of normal and impaired elimination of antibiotics]. Antibiot Khimioter (1989) 0.75
[Pharmacokinetic interpretation of the myorelaxant effect of kanamycin]. Antibiotiki (1980) 0.75
[Pharmacokinetic interpretation of the nephrotoxic effect of aminoglycosides. Pharmacokinetic aspects of nephrotoxicity of aminoglycosides]. Antibiot Khimioter (1989) 0.75
[Utilization of a mathematical model of the pharmacokinetics of streptomycin for maintaining its concentration in the blood at a given level under conditions of intravenous infusion]. Antibiotiki (1974) 0.75
[Pharmacokinetic study of implantable gentamycin preparations. I. Antibiotic pharmacokinetics in the implantation area and an evaluation of the prolonged effect of the preparations]. Antibiot Khimioter (1988) 0.75
In vitro dynamic model for determining the comparative pharmacology of fluoroquinolones. Am J Health Syst Pharm (1999) 0.75
[Pharmacokinetics of azlocillin in critical conditions: an individualized schedule of drug administration in relation to anatomo-physiologic and pathologic factors]. Antibiot Khimioter (1989) 0.75
[Mathematical models of pharmacokinetics in chemotherapy]. Pharmazie (1976) 0.75
[Pharmacokinetic prediction of the efficacy of using sisomicin in wound infections]. Antibiotiki (1983) 0.75
[Pharmacokinetic study of aclarubicin. The distribution of the preparation and its biologically active metabolites in rat tissues]. Antibiot Med Biotekhnol (1987) 0.75
[Pharmacokinetics of sisomicin during hemosorption and hemodialysis]. Antibiot Med Biotekhnol (1985) 0.75
[Clinical pharmacokinetics of the antitumor antibiotic reumycin: an analysis of individual variability]. Antibiot Med Biotekhnol (1985) 0.75
Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships. Diagn Microbiol Infect Dis (2001) 0.75
Methods for estimating drug bioavailability parameters. Part 1: Concept of biological availability and methods for estimating the extent of systemic absorption. Pharmazie (1986) 0.75
[The pharmacokinetic interpretation of the nephrotoxic effect of aminoglycosides and the influence of cephalosporins on the aminoglycoside nephrotoxic effect]. Antibiot Khimioter (1989) 0.75
[Use of a mathematical model of pharmacokinetics in the study of liver function in albino rats by the method of sulfobromophtalein test]. Lab Delo (1976) 0.75
[Pharmacokinetics of rifampicin administered intravenously to pulmonary tuberculosis patients]. Antibiot Med Biotekhnol (1987) 0.75
[The main trends in the area of the pharmacokinetic study of chemotherapeutic agents]. Antibiot Med Biotekhnol (1987) 0.75
[Graphic method of assessing the maximum cumulative excretion of a drug]. Antibiotiki (1983) 0.75
[Clinical pharmacokinetics of fluorazole]. Antibiot Khimioter (1995) 0.75
[Sisomicin pharmacokinetics in rat tissues in single and long-term administration]. Antibiotiki (1981) 0.75
[Pharmacokinetic interpretation of the nephrotoxic effect of aminoglycosides. Tests, used for controlling the status of kidney function in aminoglycoside therapy]. Antibiot Khimioter (1989) 0.75
[Pharmacokinetic validation of the antitumor efficacy of aclarubicin administered by various routes in CBF1 mice with Ca 755 carcinoma]. Eksp Onkol (1989) 0.75
[Pharmacokinetic monitoring during aminoglycoside treatment: the optimal method for individualizing the dosage of tobramycin]. Antibiot Khimioter (1989) 0.75
[Hypotension caused by intravenous infusion of rifampicin and its relation to the administration schedule]. Antibiot Khimioter (1990) 0.75
Methods for estimating drug bioavailability parameters. Part 3: Peculiarities of pharmacokinetic analysis in assessment of bioavailability. Pharmazie (1986) 0.75
[Age-related characteristics of ceftazidime pharmacokinetics in children]. Antibiot Khimioter (1992) 0.75
[Pharmacokinetic study of aclarubicin. The pharmacokinetics of the preparation and its biologically active metabolites in the blood of rats]. Antibiot Med Biotekhnol (1987) 0.75
[Kinetics of the antibacterial effect of ampicillin and sulbactam combinations in dynamic and static conditions]. Antibiot Khimioter (1989) 0.75
[Decrease of sisomicin nephrotoxicity as affected by cephalothin: pharmacokinetic evaluation]. Antibiot Med Biotekhnol (1985) 0.75
Relationship between the neuromuscular blocking effect of gentamicin and streptomycin and their concentration in blood. Acta Biol Med Ger (1977) 0.75
[Pharmacokinetic analysis of the nephrotoxic effect of sisomycin]. Antibiotiki (1981) 0.75
[Build up of a given concentration of tobramycin and sisomycin in the blood of young children by the intravenous infusion of the antibiotics according to a calculated regimen]. Antibiotiki (1982) 0.75
[A rare case of perforating injuries of both hips]. Ortop Travmatol Protez (1989) 0.75
[Pharmacokinetic interpretation of the nephrotoxic effect of aminoglycosides. Pharmacodynamic aspects of the nephrotoxic effect of aminoglycosides]. Antibiot Khimioter (1989) 0.75
[Pharmacokinetic monitoring of antibiotic therapy]. Antibiot Khimioter (1989) 0.75
[Pharmacokinetic monitoring during aminoglycosides: optimal therapy method of individual amikacin dosing]. Antibiot Khimioter (1991) 0.75
[Comparative evaluation of the antibacterial activity of aminoglycosides by means of microcalorimetry]. Antibiot Med Biotekhnol (1987) 0.75
[Dependence of the antimicrobial effect on the antibiotic concentration in modelling pharmacokinetic profiles in vitro: a comparison of 2 regimens for the single intravenous administration of sisomicin]. Antibiot Med Biotekhnol (1987) 0.75
Methods for estimating drug bioavailability parameters. Part 2: Methods for estimating absorption rate. Pharmazie (1986) 0.75
[Pharmacokinetics of cefazolin during hemosorption and hemodialysis]. Antibiot Med Biotekhnol (1986) 0.75